These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23949559)

  • 1. Risk of breast cancer by individual insulin use: an international multicenter study.
    Grimaldi-Bensouda L; Cameron D; Marty M; Barnett AH; Penault-Llorca F; Pollak M; Charbonnel B; Riddle M; Mignot L; Boivin JF; Khachatryan A; Rossignol M; Bénichou J; Alpérovitch A; Abenhaim L;
    Diabetes Care; 2014; 37(1):134-43. PubMed ID: 23949559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of insulin glargine on the risk of breast cancer.
    Suissa S; Azoulay L; Dell'Aniello S; Evans M; Vora J; Pollak M
    Diabetologia; 2011 Sep; 54(9):2254-62. PubMed ID: 21614572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
    Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
    Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins.
    Chen W; Lu J; Plum-Mörschel L; Andersen G; Zijlstra E; He A; Xie T; Li L; Hao C; Gan Z; Heise T
    Diabetes Obes Metab; 2023 Dec; 25(12):3817-3825. PubMed ID: 37735841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
    Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
    Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.
    Colhoun HM;
    Diabetologia; 2009 Sep; 52(9):1755-65. PubMed ID: 19603149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin glargine use and breast cancer risk: Associations with cumulative exposure.
    Peeters PJ; Bazelier MT; Leufkens HG; Auvinen A; van Staa TP; de Vries F; De Bruin ML
    Acta Oncol; 2016 Jul; 55(7):851-8. PubMed ID: 27150973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.
    Wu JW; Azoulay L; Majdan A; Boivin JF; Pollak M; Suissa S
    J Clin Oncol; 2017 Nov; 35(32):3647-3653. PubMed ID: 28953430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
    Hemkens LG; Grouven U; Bender R; Günster C; Gutschmidt S; Selke GW; Sawicki PT
    Diabetologia; 2009 Sep; 52(9):1732-44. PubMed ID: 19565214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes.
    Habel LA; Danforth KN; Quesenberry CP; Capra A; Van Den Eeden SK; Weiss NS; Ferrara A
    Diabetes Care; 2013 Dec; 36(12):3953-60. PubMed ID: 24170756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
    Ruiter R; Visser LE; van Herk-Sukel MP; Coebergh JW; Haak HR; Geelhoed-Duijvestijn PH; Straus SM; Herings RM; Stricker BH
    Diabetologia; 2012 Jan; 55(1):51-62. PubMed ID: 21956710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why Do Some Concentrated Insulins Maintain Their Pharmacokinetics/Pharmacodynamics Profile?
    Hood RC
    Diabetes Technol Ther; 2017 Apr; 19(4):203-205. PubMed ID: 28418731
    [No Abstract]   [Full Text] [Related]  

  • 13. Insulin glargine versus other types of basal insulin-clinical and tumor characteristics in patients with breast carcinoma.
    Besic N; Satej N
    BMC Res Notes; 2013 Oct; 6():416. PubMed ID: 24131755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin analogues for type 1 diabetes in children and adolescents.
    Galli-Tsinopoulou A; Stergidou D
    Drugs Today (Barc); 2012 Dec; 48(12):795-809. PubMed ID: 23243636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.
    Orchard TJ; Cariou B; Connelly MA; Otvos JD; Zhang S; Antalis CJ; Ivanyi T; Hoogwerf BJ
    Cardiovasc Diabetol; 2017 Jun; 16(1):73. PubMed ID: 28587667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal insulin analogues in the management of diabetes mellitus: What progress have we made?
    Owens DR; Matfin G; Monnier L
    Diabetes Metab Res Rev; 2014 Feb; 30(2):104-19. PubMed ID: 24026961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes.
    Lind M; Fahlén M; Eliasson B; Odén A
    Prim Care Diabetes; 2012 Apr; 6(1):53-9. PubMed ID: 22056422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin.
    Stürmer T; Marquis MA; Zhou H; Meigs JB; Lim S; Blonde L; Macdonald E; Wang R; Lavange LM; Pate V; Buse JB
    Diabetes Care; 2013 Nov; 36(11):3517-25. PubMed ID: 23877991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
    Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
    J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.